Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

44 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q4 2023.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,865,624 shares of 31,306,673 outstanding shares and own 47% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (4,810,508 shares), PERCEPTIVE ADVISORS LLC (3,007,858 shares), Sands Capital Ventures, LLC (1,652,605 shares), CITADEL ADVISORS LLC (1,649,659 shares), WELLINGTON MANAGEMENT GROUP LLP (888,130 shares), MARSHALL WACE, LLP (597,469 shares), BlackRock Inc. (565,832 shares), VANGUARD GROUP INC (475,977 shares), FEDERATED HERMES, INC. (226,375 shares), and GEODE CAPITAL MANAGEMENT, LLC (189,200 shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.